Novartis Ag (NVS) Long-Term Deferred Tax (2017 - 2025)

Novartis Ag (NVS) has disclosed Long-Term Deferred Tax for 9 consecutive years, with $5.4 billion as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 24.75% to $5.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.4 billion through Dec 2025, up 24.75% year-over-year, with the annual reading at $5.4 billion for FY2025, 24.75% up from the prior year.
  • Long-Term Deferred Tax hit $5.4 billion in Q4 2025 for Novartis Ag, up from $4.4 billion in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $5.4 billion in Q4 2025 to a low of $3.7 billion in Q4 2022.
  • Historically, Long-Term Deferred Tax has averaged $4.3 billion across 5 years, with a median of $4.3 billion in 2023.
  • Biggest five-year swings in Long-Term Deferred Tax: dropped 4.83% in 2021 and later grew 24.75% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $3.7 billion in 2021, then dropped by 0.11% to $3.7 billion in 2022, then grew by 15.24% to $4.3 billion in 2023, then increased by 1.16% to $4.4 billion in 2024, then increased by 24.75% to $5.4 billion in 2025.
  • Business Quant data shows Long-Term Deferred Tax for NVS at $5.4 billion in Q4 2025, $4.4 billion in Q4 2024, and $4.3 billion in Q4 2023.